Glioblastoma Multiforme Trials

Glioblastoma Multiforme

  • Newly Diagnosed Glioblastoma Multiforme - A Phase II study of Avastin® (Bevacizumab) and Tarceva® (Erlotinib) after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma multiforme without MGMT promoter methylation (more information)
  • Newly Diagnosed Glioblastoma Multiforme (Peptide Vaccine Immunotherapy) - Phase llb clinical trial of an investigational vaccine (ICT-107) for the treatment of newly diagnosed GBM following resection and chemo-radiation. (more information)
  • Newly Diagnosed Glioblastoma Multiforme and Unmethylated MGMT - Core Study - Cilengtide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter. open-label Phase II study, investigating two cilengtide regimens in combination with standard treatment temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy. (more information)
  • Recurrent Glioblastoma Multiforme: RTOG 0929 - A Randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent (temozolomide resistant) glioblastoma (RTOG 0929).  (more information)
  • Initial Recurrence of Glioblastoma Multiforme - A Phase 2 study of MEDI-575 in adult subjects with recurrent glioblastoma multiforme (more information)
Android app on Google Play